Login to Your Account



Clinic Roundup


Friday, November 8, 2013
• Biocryst Pharmaceuticals Inc., of Research Triangle Park, N.C., said it dosed the first subject in OPuS-1 (Oral ProphylaxiS-1), a Phase IIa trial testing orally administered BCX4161 in patients with hereditary angioedema.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription